COMP <GO>
MDGL vs LLY // EV/EBITDA & P/E VALUATION
Madrigal Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MDGL 3
— LLY 11
■ METRIC PARITY
LAST: $430.36 (-0.31%) • MKT CAP: $9.97B
valuation
—
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDGL VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDGL | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.70% | 32.36% | -62.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.91% | 2.30% | -4.21 | LLY | /fcf-yield <GO> |
| Operating Margin | -31.30% | 40.21% | -71.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | -30.10% | 31.90% | -62.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 45.51% | +134.49 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.65 | 9.29 | -1.64 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.5 | 77.9 | -48.38 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.51 | +0.57 | MDGL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 26.3x | -2.25 | MDGL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.97B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDGL REV | LLY REV | MDGL GROSS % | LLY GROSS % | MDGL FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $958.4M | $65.18B | 44.0% | 83.0% | -$190.0M | $16.81B |
| FY 2024 | $180.1M | $45.04B | 96.5% | 81.3% | -$457.0M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | -$324.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDGL // BETA 1.08
LLY // BETA 0.51